Inventiva (IVEVF) Net Margin (2020 - 2021)
Inventiva (IVEVF) posted Net Margin of 15184.62% for Q2 2021, down 205.59% on a QoQ basis from 4968.92% in Q1 2021, and down 328732.0% year-over-year from N/an in Q2 2020.
Powered by 
Analysis
Inventiva (IVEVF) Net Margin (2020 - 2021) Analysis & Trends
Inventiva has reported Net Margin for 2 years, with the latest figure at 15184.62% in Q2 2021.
- On a quarterly basis, Net Margin fell 328732.0% year-over-year to 15184.62% in Q2 2021; TTM through Jun 2021 was 19161.67%, a N/A change from a year earlier, with the FY2025 full-year figure at 1786.75%, up 184589.0% from the prior year.
- Net Margin was 15184.62% for Q2 2021 at Inventiva, down from 4968.92% in the prior quarter.
- The five-year high for Net Margin was 4968.92% in Q1 2021, with the low at 15184.62% in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.04 Bn | 624.28 Bn | 17.26 Bn | 21.86% |
| 2 | AbbVie | 440.25 Bn | 433.68 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 365.65 Bn | 358.51 Bn | 12.21 Bn | -8.05% |
| 4 | Novartis Ag | 266.64 Bn | 258.95 Bn | 11.24 Bn | 22.65% |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | -1.58% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 2.96% |
| 7 | Revolution Medicines | 44.19 Bn | 44.19 Bn | - | - |
| 8 | Incyte | 25.29 Bn | 20.75 Bn | 1.57 Bn | 34.98% |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 42.51% |
| 10 | Inventiva | 693.72 Mn | 693.72 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | -15,184.62% |
| Mar 31, 2021 | -4,968.92% |
| Jun 30, 2020 | -11,897.30% |
| Mar 31, 2020 | -7,783.91% |